New research suggests that many people who stop using GLP-1 drugs like Ozempic maintain their weight loss, countering previous studies Many patients using highly effective GLP-1 drugs may not regain ...
GLP-1 drugs may be able to sustain their weight loss effects even months after discontinuing the popular obesity drugs, ...
nference’s federated AI platform is being leveraged to provide access to the deepest clinical data to generate insights and better inform decision-making CAMBRIDGE, Mass.--(BUSINESS WIRE)--nference, a ...
CAMBRIDGE, Mass., May 4, 2021 /PRNewswire/ -- nference, the AI-driven health technology company, today announced that it has been named as a finalist in the Fast Company World Changing Ideas Awards in ...
CAMBRIDGE, Mass., March 23, 2021 /PRNewswire/ -- nference, the AI-driven health technology company, today announced publication in EClinicalMedicine of study "Pre-existing conditions are associated ...
CAMBRIDGE, Mass., April 17, 2025 /PRNewswire/ -- nference, a company dedicated to transforming healthcare by making biomedical data computable, today announced a collaboration with BeiGene, Ltd, a ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--nference, a science-first software company transforming healthcare data for research and discovery, and Emory Healthcare, the most comprehensive academic health ...
CAMBRIDGE, Mass. & LEXINGTON, Mass., March 18, 2025--(BUSINESS WIRE)--Valo Health, Inc. ("Valo"), a biotechnology company focused on transforming the drug discovery and development process using human ...
EHR data company nference on Wednesday launched its real-world evidence generation platform and expanded its existing partnership with the Mayo Clinic. The platform, dubbed nSights, collects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback